Theravance Biopharma Inc (TBPH NASDAQ) stock market data APIs
$10.6932
-0.08(-0.7%)
as of June 18, 2025
Try our APIs with
free plan!
Theravance Biopharma Inc Financial Data Overview
Prev. Close
10.6932
Open
10.6096
High
10.7649
Low
10.5523
52 wk Range
7.44-11.82
Market Cap
538 M
Shares Outstanding
50 001 K
Revenue
65 266 K
EPS
-0.1734
Beta
-0.079
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theravance Biopharma Inc data using free add-ons & libraries
Get Theravance Biopharma Inc Fundamental Data
{
"General": {
"Code": "TBPH",
"Type": "Common Stock",
"Name": "Theravance Biopharma Inc",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG004HK6YX1",
"ISIN": "KYG8807B1068",
"CUSIP": "G8807B106",
"CIK": "0001583107",
"EmployerIdNumber": "98-1226628",
"FiscalYearEnd": "December",
"IPODate": "2014-05-16",
"InternationalDomestic": "Domestic",
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": "Domestic",
"IsDelisted": false,
"Description": "Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampre..."
}
}Theravance Biopharma Inc Fundamental data includes:
- Net Revenue: 65 266 K
- EBITDA: -43 972 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theravance Biopharma Inc News
New
Theravance and Mylan settle patent dispute with Eugia Pharma
[Close-up of accusation and protection sides with juridical documents] AnnaStills Theravance Biopharma (NASDAQ:TBPH [https://seekingalpha.com/symbol/TBPH]) and partner Mylan reached a settlement agre...
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance Biopharma TBPH announced that it has entered into an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK plc GSK for $225 million in cash. Theravance he...
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 a...
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance Biopharma TBPH reported first-quarter 2025 adjusted net loss of 17 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 11 cents. In the year-ago quarter, the com...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
